Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech which has worked faithfully but unsuccessfully to develop a single therapy, variously referred to as Pro 140, leronlimab, and Vyrologix.

In development of this particular treatment, CytoDyn has cast its net far and wide both geographically and in terminology of possible indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they will ever be used is an open question.

While CYDY  has been dawdling, market opportunities for leronlimab as a combination treatment in the treatment of multi-drug-resistant HIV happen to be closing.

I’m composing my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale of the last few shares of mine. My 1st CytoDyn post, “CytoDyn: What In order to Do When It is Too Good In order to Be True?”, set out all of the following prediction:

Rather I expect it to become a serial disappointer. CEO Pourhassan presented such a very promotional image in the Uptick Newswire job interview that I came away with a poor viewpoint of the company.

Irony of irony, the bad impression of mine of the company has grown steadily, although the disappointment has not been financial. Two years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is it that gives a > 6 bagger at the moment still disappoints? Therein is the story; allow me to explain.

CytoDyn acquired its much-storied treatment (which I shall refer to as leronlimab) returned during 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor of the therapy as well as prevention of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical growth mAb with demonstrated anti-viral activity of HIV- infected subjects. Today’s payment of $3.5 million transfers ownership of the know-how as well as associated intellectual property from Progenics to CytoDyn, and roughly 25 million mg of bulk drug substance…. milestone payments upon commencement of a phase III clinical trial ($1.5 huge number of) and also the very first brand new drug application endorsement ($5 million), and also royalty payments of five % of net sales upon commercialization.

Since that point in time, CytoDyn’s guiding nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition into a springboard for CytoDyn to purchase a market place cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with many therapies and multiple indications, it’s this single treatment in addition to a “broad pipeline of indications” since it puts it. I call some pipelines, “pipedots.” In CytoDyn’s case it touts the leronlimab of its as a likely beneficial therapy of dozens of indications.

The opening banner of its on the website of its (below) shows an energetic business with diverse interests albeit centered on leronlimab, several illness sorts, multiple delivering presentations and multiple publications.

Might all this be smoke cigarettes and mirrors? That is a question I’ve been asking myself through the really start of the interest of mine in this organization. Judging by way of the multiples of a huge number of several commentary on listings accessible via Seeking Alpha’s CytoDyn Summary webpage, I am far from alone in this particular question.

CytoDyn is a classic battleground, or even some might say cult stock. Its adherents are fiercely protective of the prospects of its, quick to label some bad opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *